219 related articles for article (PubMed ID: 27562566)
1. Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.
D'Eufemia P; Finocchiaro R; Zambrano A; Lodato V; Celli L; Finocchiaro S; Persiani P; Turchetti A; Celli M
Osteoporos Int; 2017 Jan; 28(1):339-346. PubMed ID: 27562566
[TBL] [Abstract][Full Text] [Related]
2. Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment.
D'Eufemia P; Finocchiaro R; Villani C; Zambrano A; Lodato V; Palombaro M; Properzi E; Celli M
Pediatr Res; 2014 May; 75(5):626-30. PubMed ID: 24518563
[TBL] [Abstract][Full Text] [Related]
3. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
5. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study.
Idolazzi L; Fassio A; Viapiana O; Rossini M; Adami G; Bertoldo F; Antoniazzi F; Gatti D
Bone; 2017 Oct; 103():144-149. PubMed ID: 28684193
[TBL] [Abstract][Full Text] [Related]
6. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
7. Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1.
Faienza MF; Tummolo A; Celli M; Finocchiaro R; Piacente L; Di Serio F; Nicchia GP; Brunetti G; D'Eufemia P
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830994
[TBL] [Abstract][Full Text] [Related]
8. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
[TBL] [Abstract][Full Text] [Related]
9. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
10. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.
Maines E; Monti E; Doro F; Morandi G; Cavarzere P; Antoniazzi F
J Bone Miner Metab; 2012 Jul; 30(4):434-8. PubMed ID: 22065238
[TBL] [Abstract][Full Text] [Related]
11. Effect of macro-creatine kinase and increased creatine kinase BB on the rapid diagnosis of patients with suspected acute myocardial infarction in the emergency department.
Serdar MA; Tokgoz S; Metinyurt G; Tapan S; Erinç K; Haşimi A; Kenar L; BilgI C; Kutluay T
Mil Med; 2005 Aug; 170(8):648-52. PubMed ID: 16173202
[TBL] [Abstract][Full Text] [Related]
12. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
14. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
15. Intravenous neridronate in adults with osteogenesis imperfecta.
Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
[TBL] [Abstract][Full Text] [Related]
16. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions.
Brizola E; Shapiro JR
Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113
[TBL] [Abstract][Full Text] [Related]
20. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
Sousa T; Bompadre V; White KK
J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
